IN8bio
@In8bio
Followers
365
Following
74
Statuses
355
Clinical stage biopharmaceutical company focusing on gamma-delta T cells for the treatment of cancer. #CancerZero #IN8bio $INAB
Joined July 2017
IN8bio's COO, Kate Rochlin, PhD, will present a poster today at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Honolulu, Hawaii. She will present new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100 for AML, an allogeneic gamma-delta T cell therapy designed to help patients with complex leukemias, including AML. We hope to see you at #Tandem25! $INAB
0
1
3
RT @willhonyc: So proud of the @In8bio team and truly honored to partner with Dr. McGuirk and the whole @KUCancerCenter team. Together we…
0
4
0
IN8bio reports positive results from the Phase 1 Trial of INB-100 in Leukemia patients, with 100% of acute myeloid leukemia (AML) patients across both the original and expansion cohorts remaining in complete remission (CR), with a median follow-up of 20.1 months. We are demonstrating prolonged and durable remissions with INB-100 in this difficult-to-treat patient population as we continue our mission of achieving Cancer Zero, the safe eradication of all cancer cells from patients. Read More: $INAB
0
0
8
Register here:for today’s webcast at 8:30 AM EST. A replay will be available.
0
0
2
Our CEO and Co-founder, William Ho, will participate in a panel discussion at the BIO CEO & Investor Conference in New York tomorrow, February 11th, at 10 AM EST on “Solid Tumor Advances: T-Cell Engagers, Radioligands, and More.” @IAmBiotech $INAB
0
0
6
We are pleased to announce that IN8bio's CSO and co-founder, Lawrence Lamb, PhD, will participate in a panel discussion at the 24th Precision Medicine World Conference (PMWC 2025) today at 2pm PST. Dr. Lamb will be participating in the session titled, “Allogeneic Cell Therapies: Overcoming Hurdles and Expanding Applications,” where he will discuss his more than 30 years of clinical and translational research focused on innovative cellular immunotherapies including his insights on the role of gamma-delta T cells. $INAB @PMWCintl #PMWC25
0
1
6
Cancer impacts all of us, whether it is a personal battle or you are supporting a friend, coworker, or family member. Each story is unique. This World Cancer Day, we stand in solidarity with the Union for International Cancer Control (UICC) and all those dedicated to raising cancer awareness. At IN8bio, we strive daily to bring cutting-edge treatments to the clinic using our DeltEx gamma-delta T cell technologies with the goal of achieving our “Cancer Zero” mission ─ the safe elimination of all cancer cells in patients. We believe that one day that Cancer Zero can be a reality. $INAB #UnitedByUnique
0
1
4
RT @willhonyc: Wrapping up #JPM2025, the mood seemed quite dour, especially on the buy side. However, starting the week on the oncology pan…
0
3
0
With our roots in Alabama, where the Civil Rights Movement began, we pay tribute to the legacy of Dr. Martin Luther King Jr. and his tireless commitment to equality, justice, and progress. At IN8bio, we are committed to Birmingham and dedicated to our #CancerZero mission of continuing to make progress and bringing new therapies for difficult-to-treat cancers. We believe the words of Dr. King resonate today in the fight against Cancer, that, "Change does not roll in on the wheels of inevitability, but comes through continuous struggle" and we continue to work each day to help patients and their families. #MLKJrDay $INAB
0
0
4
Our CEO and co-founder, William Ho, will present at #BiotechShowcase 2025 in San Francisco, CA! He will participate in a panel on Monday, January 13th and deliver a company presentation on Tuesday, January 14th. Read more: $INAB #JPM25 #GDTCells
0
0
6
We have made remarkable progress with our gamma-delta T cell therapies this year as we advance our #CancerZero mission. We look forward to continuing together in 2025! Happy New Year from all of us at IN8bio! #IN8bio $INAB #GDTCells #Oncology
1
0
7
RT @willhonyc: Yesterday, we proudly announced long-term PFS data in our Ph 1 trial of INB-100 allogeneic #gdTcells for #Leukemia at #ASH24…
0
5
0
#NEWS: IN8bio reports continued progression-free survival in Phase 1 investigator-sponsored trial of INB-100 allogeneic gamma-delta T cells for Leukemias at the 2024 American Society of Hematology Annual Meeting in San Diego, CA. Read more: $INAB #CancerZero #CellTherapy #GDTcells #Oncology @ASH_hematology #ASH24
0
1
6
We are pleased to announce that our CEO and Co-Founder, William Ho, will present at the Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3rd at 10:30 am EST. Read today's press release for full details and webcast information: #CancerZero $INAB #IN8bio @NobleCapMkts #NobleCapitalMarkets
0
1
5
We are thankful for the dedication and support of our amazing employees, families, patients, researchers, and collaborators. Your hard work and support help us advance our #CancerZero mission daily. Thank you for everything you do! Happy Thanksgiving from the IN8bio Team.
0
0
3
#NEWS: IN8bio presented results from the fully enrolled Phase 1 trial of INB-200 in a plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology in Houston, TX. Read more: $INAB #SNO2024 #CancerZero #CellTherapy #GDTcells #GBM #Oncology @NeuroOnc
0
1
4
